Maria Eugenia Suarez-Almazor MD
Chief, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, Division of Internal Medicine; Deputy Department Chair (Research), Department of General Internal Medicine, Division of Internal Medicine; Barnts Family Distinguished Professor, Department of General Internal Medicine, Division of Internal Medicine at The University of Texas MD Anderson Cancer Center
Join to View Full Profile
1515 Holcombe Blvd.Houston, TX 77030
Phone+1 713-792-6161
Dr. Suarez-Almazor is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Buenos AiresClass of 1979
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2006 - 2028
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Interaction Between Patient and Healthcare Provider: Response to Acupuncture in Knee Osteoarthritis Start of enrollment: 2002 Sep 01
- Enhancing Knowledge Implantable Cardioverter-Defibrillators (ICDs) Start of enrollment: 2009 Jan 01
- Understanding Patient's Knowledge and Use of Acetaminophen Start of enrollment: 2008 Dec 19
Publications & Presentations
PubMed
- Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study.Alice Tison, Deanna Jannat-Khah, Laura C Cappelli, Maria E Suarez-Almazor, Noha Abdel-Wahab
Journal for Immunotherapy of Cancer. 2026-05-28 - Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rh...Yuanteng J Li, Maria Angeles Lopez-Olivo, Yimin Geng, Jean H Tayar, Maria E Suarez-Almazor
The Cochrane Database of Systematic Reviews. 2026-05-20 - Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study.Deanna P Jannat-Khah, Pankti Reid, Laura C Cappelli, Maria E Suarez-Almazor, Noha Abdel-Wahab
Annals of the Rheumatic Diseases. 2026-04-10
Authored Content
- Myositis as an Adverse Event of Immune Checkpoint Blockade for Cancer TherapyMay 2018
- Myositis as an Adverse Event of Immune Checkpoint Blockade for Cancer TherapyMay 2018
- Myositis as an Adverse Event of Immune Checkpoint Blockade for Cancer TherapyMay 2018
Press Mentions
For Men on ADT, Checking Bone Density May Thwart FracturesApril 1st, 2022
With Autoimmunity, Checkpoint Inhibitors Can Be UsedAugust 14th, 2019
Immune‐Related Adverse Events with the Use of Checkpoint Inhibitors for Immunotherapy of CancerJanuary 14th, 2017
Grant Support
- Methods Training for Comparative Effectiveness Research in CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
- Effects of biologic and targeted therapies for rheumatoid arthritis on cancer outcomesUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2025
- Outcomes Research In Rheumatic Diseases: A Mentoring ProgramNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2006–2011
- Adaptation Of Consumer Guides For Patients With Low Health LiteracyAgency For Healthcare Research And Quality2010
- Patient Awareness And Consumer Education Research Cente*Agency For Healthcare Research And Quality2006–2010
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
